After Barclays and J.P. Morgan gave Vir Biotechnology (NASDAQ: VIR) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau initiated coverage with a Buy rating on Vir Biotechnology yesterday. The company’s shares closed last Monday at $12.85, close to its 52-week low of $12.63.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.2% and a 46.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Vir Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $26.00, which is a 102.0% upside from current levels. In a report issued on November 5, Barclays also initiated coverage with a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.50 and a one-year low of $12.63. Currently, Vir Biotechnology has an average volume of 350.2K.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VIR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Read More on VIR:
